Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis

· seekingalpha.com

Monte Rosa Therapeutics is rated a risky Buy, as $580 million cash leaves its pipeline worth about $215 million, with MRT-6160 and MRT-2359 catalysts.

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI